No attachments available.
A--Drug Manufacturing and Formulation Program (DMFP)
Contact and place of performance
PLUGGE, RIEKA N
Kansas City, MO
USA
Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts with a maximum ordering value of $49,999,999.00 and an ordering period from May 4, 2026 through May 3, 2036, were awarded on May 4, 2026. Concurrently, the first task orders were issued to each awardee with an effective date of May 4, 2026 through July 3, 2026, in the firm-fixed price amount totaling $5,000.00.
The National Institutes of Health, specifically the National Institute on Drug Abuse (NIDA), awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for the Drug Manufacturing and Formulation Program (DMFP) on May 4, 2026. This award notice, identified by solicitation number 75N95024R00077, carries a maximum ordering value of $49,999,999.00 across a ten-year ordering period ending May 3, 2036. The program is classified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC AN11 for Health R&D Services; Health Care Services; Basic Research. No set-aside was used for this procurement.
Work will be performed in Kansas City, MO, under the management of contracting officer Rieka N. Plugge. Concurrently with the IDIQ awards, the agency issued the first task orders to each of the four awardees. These initial firm-fixed price task orders total $5,000.00 and have a performance period effective from May 4, 2026, through July 3, 2026. The contract involves health-related research and development services centered on drug manufacturing and formulation requirements.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.